Veraxa Biotech Holding AG is an oncology-focused biotechnology company engaged in the research, development, and commercialization of novel antibody-based therapeutics. The company specializes in developing targeted cancer treatments using its proprietary BiTAC-TCE platform and genetic code expansion technology. Its core activities include preclinical and clinical development of drug candidates such as VX-A901 for acute myeloid leukemia and VX-A902 targeting solid tumors, leveraging in-licensed platforms like Hemibody and internal innovations in click chemistry and protein engineering.

Veraxa Biotech Holding AG generates revenue primarily through the advancement and potential licensing of its drug development pipeline, as well as through strategic collaborations and licensing agreements with pharmaceutical and biotechnology partners. The company does not currently market any approved products, so its revenue stems from upfront payments, milestone achievements, and research funding tied to its proprietary technologies. These include its tetrazine-based click chemistry platform, genetic code expansion systems, and bispecific T-cell engaging antibodies, which are licensed to partners for co-development or commercialization.

The company operates through the following segments:

• BiTAC-TCE Platform: This segment focuses on the development of bispecific T-cell engaging antibodies designed to redirect T-cells to tumor cells for targeted cancer therapy. It utilizes the company’s proprietary BiTAC technology, which enables conditional activation of T-cell engagers specifically within the tumor microenvironment. Key trademarks associated with this segment include BiTAC, which is registered in multiple jurisdictions including the United States, Europe, and China, and supports the branding of its T-cell engaging antibody candidates.

• Genetic Code Expansion Technology: This segment involves the incorporation of non-canonical amino acids into proteins to enable site-specific conjugation for antibody-drug conjugates and other therapeutic proteins. The technology is supported by a broad portfolio of patents covering pyrrolysyl tRNA synthetase variants, orthogonal translation systems, and improved antibody-payload conjugates. Trademark protection under the VERAXA wordmark applies across this segment, covering classes related to biotechnology, pharmaceutical preparations, and scientific apparatus.

• Hitmaster Microfluidics Platform: This segment encompasses the company’s droplet-based microfluidic screening technology used for high-throughput antibody discovery and screening. It enables single-cell analysis, ligand-induced cellular response measurement, and precision sorting of biological particles. The platform is underpinned by multiple granted patents in the United States, Europe, Japan, and other jurisdictions, covering microfluidic droplet detection, sorting devices, and analysis of ligand-induced cell expression. While no standalone trademark is specifically cited for this platform, the VERAXA mark covers its use in diagnostic and research applications.

Veraxa Biotech Holding AG occupies a niche position in the oncology biotechnology sector, differentiating itself through its integrated platform approach combining genetic code expansion, click chemistry, and conditional T-cell activation. Its competitive advantages stem from a deep intellectual property portfolio, including over 20 patent families covering core technologies such as the BiTAC-TCE system, tetrazine-based conjugation, and microfluidic screening. The company competes with other antibody-drug conjugate and bispecific antibody developers but distinguishes itself through its focus on tumor-restricted activity and reduced off-target toxicity via its Hemibody and split-antibody innovations.

Veraxa Biotech Holding AG serves pharmaceutical and biotechnology companies engaged in oncology drug development, as well as clinical trial investigators and healthcare providers involved in advanced cancer treatment. Its customers include collaboration partners such as Merck (through Ares Trading SA) and Ix Therapeutics GmbH, with whom it has established research and licensing agreements. The company also engages with academic institutions and research organizations for early-stage discovery and validation of its platform technologies.